Amneal Continues To See Value In Complexity
After A ‘Solid’ 2022, Amneal Wants To Deliver On Complex Generics And Biosimilars
With Amneal delivering what it described as a “solid” set of financials for 2022, the company has reaffirmed that it sees more value in moving increasingly into complex generics and bolstering its nascent biosimilars business.
